233 related articles for article (PubMed ID: 29619024)
1. Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene.
Casucci M; Falcone L; Camisa B; Norelli M; Porcellini S; Stornaiuolo A; Ciceri F; Traversari C; Bordignon C; Bonini C; Bondanza A
Front Immunol; 2018; 9():507. PubMed ID: 29619024
[TBL] [Abstract][Full Text] [Related]
2. Stealth transgenes enable CAR-T cells to evade host immune responses.
Grauwet K; Berger T; Kann MC; Silva H; Larson R; Leick MB; Bailey SR; Bouffard AA; Millar D; Gallagher K; Turtle CJ; Frigault MJ; Maus MV
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724463
[TBL] [Abstract][Full Text] [Related]
3. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion.
Jung IY; Narayan V; McDonald S; Rech AJ; Bartoszek R; Hong G; Davis MM; Xu J; Boesteanu AC; Barber-Rotenberg JS; Plesa G; Lacey SF; Jadlowsky JK; Siegel DL; Hammill DM; Cho-Park PF; Berger SL; Haas NB; Fraietta JA
Sci Transl Med; 2022 Nov; 14(670):eabn7336. PubMed ID: 36350986
[TBL] [Abstract][Full Text] [Related]
4. CAR-Aptamers Enable Traceless Enrichment and Monitoring of CAR-Positive Cells and Overcome Tumor Immune Escape.
Zhou H; Abudureheman T; Zheng WW; Yang LT; Zhu JM; Liang AB; Duan CW; Chen K
Adv Sci (Weinh); 2024 Mar; 11(10):e2305566. PubMed ID: 38148412
[TBL] [Abstract][Full Text] [Related]
5. Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma.
Yu Z; Li H; Lu Q; Zhang Z; Tong A; Niu T
Signal Transduct Target Ther; 2024 Jan; 9(1):16. PubMed ID: 38212320
[TBL] [Abstract][Full Text] [Related]
6. CD8
Lee SY; Lee DH; Sun W; Cervantes-Contreras F; Basom RS; Wu F; Liu S; Rai R; Mirzaei HR; O'Steen S; Green DJ; Shadman M; Till BG
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38251688
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity-induced NGF-NGFR communication inefficiency promotes mitotic spindle disorganization in exhausted T cells through PREX1 suppression to impair the anti-tumor immunotherapy with PD-1 mAb in hepatocellular carcinoma.
Wang X; Yang T; Shi S; Xu C; Wang F; Dai D; Guan G; Zhang Y; Wang S; Wang J; Zhang B; Liu P; Bai X; Jin Y; Li X; Zhu C; Chen D; Xu Q; Guo Y
Cancer Med; 2024 Feb; 13(3):e6736. PubMed ID: 38204220
[TBL] [Abstract][Full Text] [Related]
8. Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial.
Guest RD; Kirillova N; Mowbray S; Gornall H; Rothwell DG; Cheadle EJ; Austin E; Smith K; Watt SM; Kühlcke K; Westwood N; Thistlethwaite F; Hawkins RE; Gilham DE
Cancer Immunol Immunother; 2014 Feb; 63(2):133-45. PubMed ID: 24190544
[TBL] [Abstract][Full Text] [Related]
9. Manufacturing Cell and Gene Therapies: Challenges in Clinical Translation.
Lee NK; Chang JW
Ann Lab Med; 2024 Jul; 44(4):314-323. PubMed ID: 38361427
[TBL] [Abstract][Full Text] [Related]
10. RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells.
Bouquet L; Bôle-Richard E; Warda W; Neto Da Rocha M; Trad R; Nicod C; Haderbache R; Genin D; Ferrand C; Deschamps M
Gene Ther; 2023 Sep; 30(9):706-713. PubMed ID: 37173386
[TBL] [Abstract][Full Text] [Related]
11. Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output.
Song HW; Benzaoui M; Dwivedi A; Underwood S; Shao L; Achar S; Posarac V; Remley VA; Prochazkova M; Cai Y; Jin P; Somerville RP; Stroncek DF; Altan-Bonnet G; Shah NN; Chien CD; Taylor N; Highfill SL
Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101171. PubMed ID: 38298420
[TBL] [Abstract][Full Text] [Related]
12. In vivo manufacture and manipulation of CAR-T cells for better druggability.
Hou R; Zhang X; Wang X; Zhao X; Li S; Guan Z; Cao J; Liu D; Zheng J; Shi M
Cancer Metastasis Rev; 2024 Apr; ():. PubMed ID: 38592427
[TBL] [Abstract][Full Text] [Related]
13. A positive take on negative selection for CAR-T manufacturing.
Orentas RJ
Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101218. PubMed ID: 38445044
[No Abstract] [Full Text] [Related]
14. CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications.
Köhl U; Arsenieva S; Holzinger A; Abken H
Hum Gene Ther; 2018 May; 29(5):559-568. PubMed ID: 29620951
[TBL] [Abstract][Full Text] [Related]
15. Celyad's novel CAR T-cell therapy for solid malignancies.
Lonez C; Hendlisz A; Shaza L; Aftimos P; Vouche M; Donckier V; Machiels JH; Van Den Eynde M; Canon JL; Carrasco J; Odunsi K; Sahebjam S; Rottey S; Braun N; Verma B; Gilham DE; Lehmann FF
Curr Res Transl Med; 2018 May; 66(2):53-56. PubMed ID: 29625833
[TBL] [Abstract][Full Text] [Related]
16. Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment.
Arai Y; Choi U; Corsino CI; Koontz SM; Tajima M; Sweeney CL; Black MA; Feldman SA; Dinauer MC; Malech HL
Mol Ther; 2018 May; 26(5):1181-1197. PubMed ID: 29622475
[TBL] [Abstract][Full Text] [Related]
17. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.
Crossland DL; Denning WL; Ang S; Olivares S; Mi T; Switzer K; Singh H; Huls H; Gold KS; Glisson BS; Cooper LJ; Heymach JV
Oncogene; 2018 Jul; 37(27):3686-3697. PubMed ID: 29622795
[TBL] [Abstract][Full Text] [Related]
19. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M
Mount CW; Majzner RG; Sundaresh S; Arnold EP; Kadapakkam M; Haile S; Labanieh L; Hulleman E; Woo PJ; Rietberg SP; Vogel H; Monje M; Mackall CL
Nat Med; 2018 May; 24(5):572-579. PubMed ID: 29662203
[TBL] [Abstract][Full Text] [Related]
20. Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.
Smith EL; Staehr M; Masakayan R; Tatake IJ; Purdon TJ; Wang X; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Riviere I; Liu C; Brentjens RJ
Mol Ther; 2018 Jun; 26(6):1447-1456. PubMed ID: 29678657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
